Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
December 8, 2020
Ryan Allway December 8th, 2020 Psychedelics Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybin DENVER, Dec. 08, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging... Read more
Nova Mentis Appoints Dr. Marvin S. Hausman as Chairman of Scientific Advisory Board
December 4, 2020
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
PsyBio Therapeutics and Leo Acquisitions Announce Closing of CAD$14.5 Million Oversubscribed Private Placement
December 4, 2020
Ryan Allway December 4th, 2020 Psychedelics PsyBio Therapeutics, Inc. (“PsyBio”) and Leo Acquisitions Corp. (NEX: LEQ.H) (“Leo”) are pleased to announce the closing of the previously announced brokered private placement (the “Financing”) of subscription receipts (the “Subscription Receipts”) of PsyBio Therapeutics Financing Inc. (“Finco”), a special purpose British Columbia... Read more
Havn Life Sciences Partners With Veterans Mental Health Non-Profit, Westwood Institute
December 4, 2020
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Field Trip Health Ltd. Provides Operational and Investor Update
December 4, 2020
Ryan Allway December 4th, 2020 Psychedelics Field Trip Health Ltd. (CSE: FTRP) (OTCBB: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, is pleased to announce that, in response to significant interest from people and medical professionals in Canada, it is expanding the hours of... Read more
Lobe Sciences Commences Engineering of Nasal Mist Device
December 4, 2020
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform
December 2, 2020
Ryan Allway December 2nd, 2020 Psychedelics PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has amended its sponsored research agreement with... Read more
Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group
December 2, 2020
Ryan Allway December 2nd, 2020 Psychedelics Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (“Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has become a voting member of the Conservative Drug Policy... Read more
Field Trip Health Ltd. Reports Second Fiscal Quarter 2021 Financial Results, Announces Two New Field Trip Health Center Locations
December 1, 2020
Ryan Allway December 1st, 2020 Psychedelics, Top News November 30, 2020 17:05 ET | Source: Field Trip Health, Ltd. Pre-clinical studies demonstrate potential of FT-104, its novel psychedelic molecule, as preferable option for psychedelic therapies, with comparable potency to psilocybin and shorter duration 4 Field Trip Health centers are in operation, with... Read more
Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine
November 30, 2020
Ryan Allway November 30th, 2020 Psychedelics Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC“) for the treatment of mild traumatic brain injury/concussion (“mTBI“) with post-traumatic stress disorder (“PTSD“). The study... Read more
